Overview

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants

Status:
COMPLETED
Trial end date:
2019-03-08
Target enrollment:
Participant gender:
Summary
Primary Objective 1. To evaluate the tolerability, safety of single and multiple doses of YZJ-1139 in healthy participants 2. To evaluate the pharmacokinetic of single and multiple doses of YZJ-1139 in healthy participants Secondary objectives: To explore the safe tolerated dose of YZJ-1139, provide data support for the design of phase II dosing regimen
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.